Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- November30 2003
- Volume 10
- Issue 22
Losing Ground
Advertisement
2%—The 5-year average annual compensationincrease for a primary care physician in the United State.
Source: Medical Group Management Association, 2003
Articles in this issue
about 18 years ago
A Wedding Isn't Really About the Moneyabout 18 years ago
Protect Your Future with Smart Planningabout 18 years ago
Watch Out for Retirement Plan Tax Trapsabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Reconsider Taxable Retirement Accountsabout 18 years ago
Benefit from Social Security Knowledgeabout 18 years ago
Understand Physicians' Financial Phasesabout 18 years ago
Take Time to Build, and Later to Mournabout 18 years ago
Prepare for Tomorrow's Realities Todayabout 18 years ago
26 Tips for Avoiding Medical MalpracticeAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5